BioSpace News Archive

Qualigen Therapeutics, Inc. (Nasdaq: QLGN), today announces the presentation of two posters on the Company’s lead compound, QN-302, at the American Academy of Cancer Research’s (AACR) 8th Special Conference on Pancreatic Cancer being held on September 13-16, 2022 in Boston.

Travere Therapeutics, Inc. announced that on September 10, 2022, the Compensation Committee of its Board of Directors granted inducement equity grants to 16 new employees, consisting of inducement restricted stock units, or RSUs, covering an aggregate of 79,600 shares of its common stock.

Astrocyte Pharmaceuticals Inc., a private drug discovery and development company advancing novel cerebroprotective therapeutics for patients with brain injuries, today provided an update on the preclinical and clinical development of its lead drug candidate, AST-004, in preclinical brain injury studies and in an ongoing clinical Phase 1 study.

Radiation therapy or radiotherapy has emerged as a cost-effective cancer treatment modality and gained significance in reducing morbidity and mortality due to cancer.

Ornithine transcarbamylase deficiency, a highly common urea cycle disorder and rare X-linked genetic disorder, is characterized by partial or a complete lack of enzyme ornithine transcarbamylase (OTC)

Single-photon emission computed tomography (SPECT) is a nuclear imaging technique that uses radioactive tracers and a scanner to record data to produce two or three-dimensional images.

Gemini BioProducts Holding, Inc. (“GeminiBio” or the “Company”), a portfolio company of BelHealth Investment Partners, LLC (“BelHealth”), a Florida-based healthcare private equity firm, announced the appointment of Cory Stevenson to its Board of Directors.

Gameto announced that it has raised an additional $17 million in funding from global software investor Insight Partners, Future Ventures, Arcadia Investment Partners, Bold Capital Partners, Plum Alley, Myelin VC, TA Ventures, Gaingels, Korify Capital, and other existing investors.

Ventria Bioscience Inc. (Ventria) today announced that the United States International Trade Commission (ITC) completed its review of Administrative Law Judge McNamara’s previous determination and affirmed the prior ruling that Wuhan Healthgen and its distributors violated Section 337 by importing into the United States products that infringe Ventria’s patent and which were marketed and sold without being labeled as originating from China.

Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company focused on transforming the lives of patients and their families living with hyperphagia and severe obesity caused by rare melanocortin-4 receptor pathway diseases, announced a proposed public offering of $100 million of shares of its common stock.